US US20260229351A1
A quantum-dot-enhanced CRISPR-Cas13a microfluidic molecular triage and clinical routing system for rapid high-risk human papillomavirus genotyping in cervical and breast cancer care pathways includes a disposable microfluidic cartridge and a reader for rapid genotyping of high-risk human papillomavirus from cervical samples. The cartridge includes a sample inlet, lysis zone, CRISPR reaction zone, optical detection zone, and waste reservoir. At least one reaction microchannel has a width of about 100 micrometers and a depth of about 50 micrometers. A CRISPR-Cas13a assay is incubated at about 37 degrees Celsius for about 15 minutes. Fluorescence from a quantum-dot reporter having a peak emission at about 605 nanometers is detected to generate a same-visit triage output indicating HPV16/18 positive, other high-risk HPV positive, negative, invalid, or repeat-test recommended. Optional communications features support secure transmission of results or run metadata to patient, provider, emergency, or reimbursement interfaces.
A document turning up in a search is not the same as a document that anticipates your claims. Our registered Patent Agents read the claims, not just the abstract, and tell you where you still have room.
Protect Your InventionBibliographic data via the European Patent Office's Open Patent Services (DOCDB) . Republished here for research and prior-art review. This page is not legal advice, and its presence in our index says nothing about the validity or enforceability of the document. For the Indian legal position (status, oppositions, renewals), see InPASS.